MPP  is exploring ways to improve access to long-acting insulin analogues in LMICs, where the burden of diabetes poses a profound challenge, and appropriate treatment options remain limited and/or non accessible. Analogue formulations of insulin offer significant clinical advantages over traditional human insulins that are currently the most widely used insulins in LMICs. Their improved pharmacokinetic profiles support better glycaemic control, reduce the risk of hypoglycaemia and allow for more flexible dosing schedules    . The clinical advantages of insulin analogues over human insulin led to their inclusion in the WHO Model List of Essential Medicines in 2021, recognising their potential to improve diabetes management globally. Despite these benefits, the high cost of insulin analogues continues to limit their uptake in LMICs, where human insulins remain more affordable and widely used. MPP’s engagement in this space seeks to address affordability challenges and contribute to broader access to newer, more effective diabetes treatments in underserved settings, while also monitoring progress in next-generation insulin formulations that offer sustained, longer-acting coverage with the potential to further reduce hypoglycaemia risk and ease the injection burden for people living with diabetes. Given the diversity within the class of insulin analogues, a snapshot card was not produced, as it would not adequately capture the specificities of the different products. While patents have expired for most insulin analogues (administered more often than weekly), technology transfer – including to strengthen regional manufacturing – could support an MPP intervention within this area.

Acronyms & abbreviations list